Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Aug 1;185(8):937-946.
doi: 10.1001/jamainternmed.2025.1580.

Dietary Patterns, Sodium Reduction, and Blood Pressure in Type 2 Diabetes: The DASH4D Randomized Clinical Trial

Collaborators, Affiliations
Randomized Controlled Trial

Dietary Patterns, Sodium Reduction, and Blood Pressure in Type 2 Diabetes: The DASH4D Randomized Clinical Trial

Scott J Pilla et al. JAMA Intern Med. .

Abstract

Importance: People with type 2 diabetes and hypertension are at high risk for blood pressure-related cardiovascular events. Few trials have tested the blood pressure-lowering effects of dietary interventions other than weight loss in this population.

Objective: To determine the effects of dietary patterns and sodium reduction on blood pressure in adults with type 2 diabetes.

Design, setting, and participants: Dietary Approaches to Stop Hypertension for Diabetes (DASH4D) was a randomized 4-period crossover feeding study conducted at a community-based study center from June 2021 to June 2024. It included adults with type 2 diabetes, a systolic blood pressure of 120 to 159 mm Hg, and a diastolic blood pressure of less than 100 mm Hg. The DASH4D diet is a Dietary Approaches to Stop Hypertension (DASH)-style diet optimized for people with type 2 diabetes (lower carbohydrates, higher unsaturated fats, and lower potassium than the original DASH diet). Participants were provided all of their food and ate no outside food. Weight was held constant. Data analysis was completed in November 2024.

Interventions: Participants were randomized to a sequence of 4 diets, each for 5 weeks: (1) DASH4D diet with lower sodium, (2) DASH4D diet with higher sodium, (3) comparison (typical US) diet with lower sodium, and (4) comparison diet with higher sodium (reference).

Main outcomes and measures: The primary and secondary outcomes were end-of-period systolic and diastolic blood pressure, respectively. The primary dietary contrast compared the DASH4D lower sodium diet vs a comparison higher sodium diet.

Results: Of 102 participants, 85 (83.3%) completed all diet periods. The mean (SD) age was 66 (8.8) years, 67 (66%) were women, 6 (6%) were self-reported Asian, 89 (87%) were Black, 2 (2%) were Hispanic, 6 (6%) were White, mean (SD) baseline blood pressure was 135 (9)/75 (9) mm Hg, and 67 (66%) used 2 or more antihypertensive medications. Compared with the comparison diet with higher sodium, the DASH4D diet with lower sodium reduced end-of-period systolic blood pressure by 4.6 mm Hg (95% CI, 7.2-2.0; P < .001) and diastolic blood pressure by 2.3 mm Hg (95% CI, 3.7-0.9). Most blood pressure reduction occurred during the first 3 weeks of each diet, and the effect of sodium reduction appeared stronger than the effect of the DASH4D diet. Adverse events were infrequent in each diet.

Conclusions and relevance: This randomized clinical trial found that, for adults with type 2 diabetes, most of whom were treated with multiple antihypertensive medications, the DASH4D diet combined with sodium reduction achieved a clinically relevant reduction in blood pressure, primarily from sodium reduction.

Trial registration: ClinicalTrials.gov Identifier: NCT04286555.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Pilla and Wang reported grants from the National Institutes of Health (NIH) during the conduct of the study. Ms Mitchell reported grants from Sheikh Khalifa Stroke Institute at Johns Hopkins University and the NIH during the conduct of the study. Dr Selvin reported grants from the NIH during the conduct of the study as well as grants from the NIH and personal fees from Siemens Healthineers outside the submitted work. Dr Maruthur reported grants from NIH, Maryland HSCRC, and Maryland CRF outside the submitted work. Dr Mueller reported scientific advisory board service for Tiny Health LLC outside the submitted work. Dr Appel reported grants from the Sheikh Khalifa Stroke Institute, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Heart, Lung, and Blood Institute, and the National Center for Advancing Translational Sciences during the conduct of the study as well as personal fees from UpToDate outside the submitted work. No other disclosures were reported.

Similar articles

Cited by

References

    1. Shin JI, Wang D, Fernandes G, et al. Trends in receipt of American Diabetes Association guideline-recommended care among U.S. adults with diabetes: NHANES 2005-2018. Diabetes Care. 2021;44(6):1300-1308. doi: 10.2337/dc20-2541 - DOI - PMC - PubMed
    1. Rana J, Oldroyd J, Islam MM, Tarazona-Meza CE, Islam RM. Prevalence of hypertension and controlled hypertension among United States adults: Evidence from NHANES 2017-18 survey. Int J Cardiol Hypertens. 2020;7:100061. doi: 10.1016/j.ijchy.2020.100061 - DOI - PMC - PubMed
    1. de Boer IH, Bangalore S, Benetos A, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(9):1273-1284. doi: 10.2337/dci17-0026 - DOI - PubMed
    1. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387(10017):435-443. doi: 10.1016/S0140-6736(15)00805-3 - DOI - PubMed
    1. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603-615. doi: 10.1001/jama.2014.18574 - DOI - PubMed

Publication types

Substances

Associated data